FDA Approves Broader Access for Depression Therapy

The Food and Drug Administration has granted an Intermediate Population Expanded Access Protocol for NRX-101, a D-cycloserine-based treatment. This therapy is designed to enhance transcranial magnetic stimulation for depression. The approval will allow more patients to access the treatment under compassionate care provisions.